Pegloticase + Methotrexate
ApprovedActive 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedAbout Pegloticase + Methotrexate
Pegloticase + Methotrexate is a approved stage product being developed by Amgen for Gout. The current trial status is active. This product is registered under clinical trial identifier NCT06229145. Target conditions include Gout.
What happened to similar drugs?
6 of 20 similar drugs in Gout were approved
Approved (6) Terminated (3) Active (12)
🔄SHR4640 dose1 + SHR4640 dose2 + Placebo oral tablet + Allopurinol 300 MGJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
🔄HR091506 tablets + placebo of febuxostat tablets + febuxostat tablets + placebo of HR091506 tabletsJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
20
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07388498 | Phase 3 | Recruiting |
| NCT06229145 | Approved | Active |
Competing Products
20 competing products in Gout